Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2025.116195 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Noah Zimmermann und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Fleur Hiege Center for Skin Cancer Re…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Anticoagulants, Molecular Targeted Therapy. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Targeted therapies (TT) improve outcomes in BRAF-mutant melanoma. Pre-clinical data suggest that anticoagulation (AC) and platelet aggregation inhibition (PAI) may have antitumoral effects. We evaluated the impact of concomitant AC or PAI on outcomes in patients receiving TT. METHODS: We analyzed 1296 patients with unresectable stage III-IV BRAF-mutant melanoma treated with BRAF plus MEK inhibitors (2016-2024) in the prospective multicenter ADOReg registry. Patients were categorized as receiving no antithrombotic therapy (ATT; n = 1125), PAI (n = 73; acetylsalicylic acid or clopidogrel), or AC (n = 98; direct oral anticoagulants, low-molecular-weight heparin, or vitamin K antagonists). RESULTS: Median follow-up was 1.3 years. Compared with patients without ATT, those receiving AC had significantly improved 12-month progression-free survival (PFS; HR 0.55, 95 % CI 0.39-0.78, p = 0.001) and overall survival (OS; HR 0.35, 95 % CI 0.19-0.64, p = 0.001). Direct oral anticoagulants showed the most pronounced PFS benefit (HR 0.40, 95 % CI 0.25-0.64, p < 0.001). PAI was not associated with a significant difference in PFS, but multivariable Cox regression indicated a reduced hazard of death (HR 0.48, 95 % CI 0.27-0.87, p = 0.015). CONCLUSION: Concomitant AC, particularly factor Xa-inhibiting direct oral anticoagulants, was associated with improved survival in melanoma patients undergoing TT. These findings support prospective trials evaluating AC as concomitant therapy in advanced melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Ge…
- Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
- Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
- Department of Dermatolog, Bielefeld University, Bielefeld, Germany; Medical School and University Medical Center OWL, Bielefeld, Germany.
- Department of Dermatology, Division of Dermatooncology, University Medical Center, Tuebingen, Germany.
- Department of Dermatology, Comprehensive Cancer Center Erlangen - EMN, Erlangen, Germany; Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Zitieren
APA
Zimmermann, N., Kött, J., Zell, T., Abedini, A. Z., Blomen, C. L., Belz, S., Deitert, B., Heidrich, I., Geidel, G., Rünger, A., Smit, D. J., Weichenthal, M., Ugurel, S., Leiter, U., Berking, C., Gutzmer, R., Schadendorf, D., von Wasielewski, I., Mohr, P., …, & Gebhardt, C. (2026). Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116195
Vancouver
Zimmermann N, Kött J, Zell T, Abedini AZ, Blomen CL, Belz S, et al. Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116195
BibTeX
@article{Zimmermann2026,
author = {Zimmermann, Noah and Kött, Julian and Zell, Tim and Abedini, Ali Zeinal and Blomen, Chiara L and Belz, Stella and Deitert, Benjamin and Heidrich, Isabel and Geidel, Glenn and Rünger, Alessandra and Smit, Daniel J and Weichenthal, Michael and Ugurel, Selma and Leiter, Ulrike and Berking, Carola and Gutzmer, Ralf and Schadendorf, Dirk and von Wasielewski, Imke and Mohr, Peter and Meier, Friedegund and Herbst, Rudolf and Utikal, Jochen and Terheyden, Patrick and Haferkamp, Sebastian and Pföhler, Claudia and Kaatz, Martin and Ziller, Fabian and Ulrich, Jens and Meiss, Frank and Bauer, Alexander T and Schneider, Stefan W and Gebhardt, Christoffer},
title = {Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2025.116195}
}
EUVIMED